Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't.
作者信息
Sgalla Giacomo, Mari Pier-Valerio, Richeldi Luca
机构信息
UOC Pneumologia, Dipartimento Scienze Gastroenterologiche, Endocrino-Metaboliche e Nefro-Urologiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Università Cattolica del Sacro Cuore, Rome, Italy.
出版信息
Ann Transl Med. 2020 Dec;8(23):1615. doi: 10.21037/atm-20-3243.
Abstract
摘要
相似文献
1
Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you don't.家庭肺功能测定法评估吡非尼酮在进行性不可分类间质性肺疾病中的疗效：熟知的魔鬼总比未知的魔鬼好。
Ann Transl Med. 2020 Dec;8(23):1615. doi: 10.21037/atm-20-3243.
2
Surveillance for stage I seminoma: better the devil you know than the devil you don't?对I期精原细胞瘤的监测：了解已知的风险是否好过未知的风险？
Oncology (Williston Park). 2009 Aug;23(9):762, 764.
3
Redefining endpoints with apnoeic oxygenation in pregnancy - better the devil you know than the devil you don't?重新定义孕期无呼吸氧合的终点——熟知的魔鬼总比未知的魔鬼好？
Anaesthesia. 2019 Dec;74(12):1621-1622. doi: 10.1111/anae.14882.
4
Commentary: The devil you know and the devil you don't.评论：你认识的魔鬼和你不认识的魔鬼。
J Thorac Cardiovasc Surg. 2019 Sep;158(3):835-836. doi: 10.1016/j.jtcvs.2019.03.106. Epub 2019 Apr 23.
5
Thyroid Cancer Active Surveillance: The Devil You Know or The Devil You Don't.甲状腺癌主动监测：已知的恶魔还是未知的恶魔。
Thyroid. 2022 Nov;32(11):1279-1280. doi: 10.1089/thy.2022.0541. Epub 2022 Nov 4.
6
Is the devil that you don't know ever better?你不了解的魔鬼会更好吗？
Menopause. 2008 Nov-Dec;15(6):1041-2. doi: 10.1097/gme.0b013e31818c740a.
7
Cholesterol - the devil you know; ceramide - the devil you don't.胆固醇——你了解的恶魔；神经酰胺——你不了解的恶魔。
Trends Pharmacol Sci. 2021 Dec;42(12):1082-1095. doi: 10.1016/j.tips.2021.10.001. Epub 2021 Nov 5.
8
"Better the devil you know": Are stated preferences over health and happiness determined by how healthy and happy people are?“知根知底的恶魔”：人们对健康和幸福的偏好是由人们的健康和幸福程度决定的吗？
Soc Sci Med. 2022 Jun;303:115015. doi: 10.1016/j.socscimed.2022.115015. Epub 2022 May 10.
9
A Duty to Describe: Better the Devil You Know Than the Devil You Don't.有描述的义务：宁为熟知的恶魔，不为未知的恶魔。
Perspect Psychol Sci. 2014 Nov;9(6):626-40. doi: 10.1177/1745691614551749.
10
Knowing that you don't know: metamemory and discourse processing.自知无知：元记忆与话语处理
J Exp Psychol Learn Mem Cogn. 1997 Nov;23(6):1378-93. doi: 10.1037//0278-7393.23.6.1378.
引用本文的文献
1
How to Enhance the Diagnosis of Early Stages of Chronic Obstructive Pulmonary Disease (COPD)? The Role of Mobile Spirometry in COPD Screening and Diagnosis-A Systematic Review.如何提高慢性阻塞性肺疾病（COPD）早期阶段的诊断水平？移动肺量计在 COPD 筛查和诊断中的作用——系统评价。
Adv Respir Med. 2024 Mar 27;92(2):158-174. doi: 10.3390/arm92020018.
本文引用的文献
1
Twenty-five years of Respirology: Advances in idiopathic pulmonary fibrosis.呼吸病学25年：特发性肺纤维化的进展
Respirology. 2020 Jan;25(1):20-22. doi: 10.1111/resp.13733.
2
Interstitial lung disease: perhaps unclassifiable, but not untreatable.间质性肺疾病：或许无法归类，但并非不可治疗。
Lancet Respir Med. 2020 Feb;8(2):126-127. doi: 10.1016/S2213-2600(19)30343-1. Epub 2019 Sep 29.
3
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.吡非尼酮治疗无法分类的进行性纤维化间质性肺疾病患者：一项双盲、随机、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29.
4
Understanding Progressive Fibrosing Interstitial Lung Disease through Therapeutic Trials.通过治疗试验理解进行性纤维化间质性肺疾病
N Engl J Med. 2019 Oct 31;381(18):1775-1777. doi: 10.1056/NEJMe1911794. Epub 2019 Sep 29.
5
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.尼达尼布治疗进行性纤维化间质性肺疾病。
N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.
6
Contemporary Concise Review 2018: Interstitial lung disease.《2018当代简明综述：间质性肺疾病》
Respirology. 2019 Aug;24(8):809-816. doi: 10.1111/resp.13572. Epub 2019 May 8.
7
Update in Pulmonary Fibrosis 2018.2018年肺纤维化进展
Am J Respir Crit Care Med. 2019 Aug 1;200(3):292-300. doi: 10.1164/rccm.201903-0542UP.
8
The characterisation of interstitial lung disease multidisciplinary team meetings: a global study.间质性肺病多学科团队会议的特征：一项全球研究。
ERJ Open Res. 2019 Apr 1;5(2). doi: 10.1183/23120541.00209-2018. eCollection 2019 Apr.
9
Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.进展性肺纤维化性间质性肺疾病的药物治疗管理：当前证据综述。
Eur Respir Rev. 2018 Dec 21;27(150). doi: 10.1183/16000617.0074-2018. Print 2018 Dec 31.
10
A home monitoring program including real-time wireless home spirometry in idiopathic pulmonary fibrosis: a pilot study on experiences and barriers.特发性肺纤维化患者家庭监测方案：实时无线家庭肺功能测定的试点研究——经验与障碍
Respir Res. 2018 May 29;19(1):105. doi: 10.1186/s12931-018-0810-3.
Zotero 插件